SCHEMBL14723522

SCHEMBL14723522

COC(=O)c1cnc(N2CC(NC(=O)OC(C)(C)C)C(c3cc(F)ccc3F)C2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.42
NR1H3 Q13133 2/20 0.42
NTRK1 P04629 4/20 0.40
EIF2AK4 Q9P2K8 1/20 0.36
DPP4 P27487 1/20 0.36
F2R P25116 1/20 0.36
NPY5R Q15761 4/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
RET P07949 2/20 0.35
KDM1A O60341 1/20 0.34
PDE4B Q07343 1/20 0.34
HDAC3 O15379 1/20 0.34
CYP3A4 P08684 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14723584 0.92 NR1H2 (0.41) NR1H2NR1H3NTRK1EIF2AK4F2R
SCHEMBL6128115 0.92 NTRK1 (0.41) NR1H2NTRK1EIF2AK4DPP4F2R
SCHEMBL14722979 0.92 NTRK1 (0.41) NR1H2NTRK1EIF2AK4DPP4F2R
SCHEMBL470735 0.90 NTRK1 (0.42) NR1H2NTRK1DPP4F2RNPY5R
SCHEMBL14730330 0.90 NR1H2 (0.40) NR1H2NR1H3EIF2AK4DPP4F2R
SCHEMBL14723221 0.90 NR1H2 (0.40) NR1H2NR1H3EIF2AK4DPP4F2R
SCHEMBL14723597 0.90 NTRK1 (0.43) NTRK1KMT2ARETHDAC1
SCHEMBL14730180 0.90 NTRK1 (0.43) NTRK1KMT2ARETHDAC1
SCHEMBL1724455 0.90 NTRK1 (0.40) NR1H2NTRK1EIF2AK4DPP4F2R
SCHEMBL610993 0.90 NTRK1 (0.40) NR1H2NTRK1EIF2AK4DPP4F2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013026587-A1 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2013-02-28 WO disclosed